-+ 0.00%
-+ 0.00%
-+ 0.00%
Repligen targets approximately 30% adjusted EBITDA margin
Share
Listen to the news
Repligen targets approximately 30% adjusted EBITDA margin
  • Repligen targets an adjusted EBITDA margin of about 30%, while investing to support sustainable growth.
  • The BioLife acquisition is still expected to deliver more than 5 cents of first-year accretion.
  • BioLife revenue is projected at $114 million in 2026, up from $75 million in 2024.
  • The outlook continues to assume an approximately 2% gene therapy headwind in fiscal 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending